<DOC>
	<DOCNO>NCT01562223</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , dynamic contrast-enhanced magnetic resonance image DCE-MRI diffusion-weighted imaging DWI , may provide image prostate cancer cancer remain biopsy . PURPOSE : This trial study repeat DCE-MRI DWI patient diagnosed prostate cancer .</brief_summary>
	<brief_title>Studying Repeated DCE-MRI DWI Patients Diagnosed With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine test-retest performance , assess repeatability coefficient [ RC ] K^trans gadolinium curve ( IAUGC90^bn ) measure median pixel value whole prostate . - Determine test-retest performance , assess RC diffusion-weighted imaging ( DWI ) metric D ( ) measure median pixel value whole prostate . Secondary - Determine test-retest performance , assess RC K^trans , IAUGC90^bn , D ( ) , measure median pixel value dominant prostate tumor . - Determine effect reader RC dynamic contrast-enhanced magnetic resonance imaging ( DCE-MRI ) DWI metric whole prostate tumor nodule target lesion . - Determine whether T1-dependent T1-independent method gadolinium quantification DCE-MRI study produce differ value RC K^trans IAUGC90^bn . - Explore correlation DCE-MRI DWI metric whole prostate dominant tumor nodule target lesion . ( Exploratory ) - Determine whether `` coffee break '' approach toward test-retest analysis quantitative DWI provide reasonable estimate RC D ( ) whole prostate , use gold standard RC D ( ) obtain two separate MRI visit . ( Exploratory ) OUTLINE : This multicenter study . Patients stratify accord MRI vendor use ( Siemens vs GE v Philips ) . Patients receive gadolinium-based contrast IV undergo DCE-MRI* DWI 2 image 2-14 day apart prior treatment initiation . A central reader evaluation 2 successive scan conduct . NOTE : *At discretion participate site , initial MRI visit ( MRI SCAN 1 ) may supplement endorectal-coil image per institutional norm .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis prostate adenocarcinoma transrectal ultrasound ( TRUS ) guide biopsy 28 90 day prior enrollment Minimal tumor burden define least one follow criterion : One single core ≥ 50 % cancer burden ≥ 5 mm tumor length Two core prostate region , ≥ 30 % cancer burden Three core positive prostate cancer ( magnitude cancer burden ) prostate region Gleason score 7 high cancer burden Prostatespecific antigen ( PSA ) ≥ 10 ng/mL PATIENT CHARACTERISTICS : Able tolerate magnetic resonance imaging ( MRI ) require protocol , perform American College Radiology Imaging Network ( ACRIN ) qualify facility scanner Not suitable undergo MRI gadoliniumbased contrast agent : Severe claustrophobia relieved oral anxiolytic per institutional standard practice Presence MRIincompatible metallic object implant medical device body ( include , limited , nonMRI compatible metal object , cardiac pacemaker , aneurysm clip , artificial heart valve steel part , metal fragment eye central nervous system ) Renal failure , determine glomerular filtration rate ( GFR ) &lt; 30 mL/min base serum creatinine level obtain within 48 hour prior enrollment Weight great allowable MRI table , per local institutional practice PRIOR CONCURRENT THERAPY : No antiandrogenic therapy within 30 day prior enrollment No prior externalbeam radiotherapy , proton radiotherapy , brachytherapy prostate No prior hip replacement major pelvic surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>